Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Oncology-focused biopharma Compass Therapeutics (NASDAQ:CMPX) announced Tuesday that tovecimig (CTX-009), its treatment for ...

Lenny Santoro was diagnosed with prostate cancer in 2011. Thanks to clinical trials Santoro participated in at the Duke ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

The former lawmaker from Utah had undergone treatment for glioblastoma, a malignant brain tumor, and received immunotherapy ...

The Toronto-based company, Altis Labs, claims its AI model is similarly superior at analyzing breast cancer and colorectal ...

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...